ClinicalTrials.gg
CompletedNCT04648852HUNT4HFUpdated Jun 15, 2025

The HUNT for Heart Failure" Risk Score

An observational study in Heart Failure, sponsored by Helse Nord-Trøndelag HF. Completed at 1 site in Norway. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-15.

Sponsored by Helse Nord-Trøndelag HF · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Ecologic or community
Time perspective
Prospective
Enrollment
36,511
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 104 studies in Heart Failure with a site in Norway — 16 open to participants now, 19 under way, 1 of them phase 3. Heart Failure · Norway.

Enrollment
Largest of 21
36,511 · median 200
Started
2017
with 3 others
Observational
21 of 104
6 open now
Registered
81st of 104
by date
Lead sponsor
8 of 104
Helse Nord-Trøndelag HF

Among the 104 studies in Heart Failure with a site in Norway, this one has the largest enrollment of the 21 observational ones that give a count, is one of 4 that started in 2017, is one of 21 observational ones, and was the 81st registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

16 of the 104 studies in Heart Failure with a site in Norway are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies in Heart Failure with a site in Norway, or all of them as a file.
02

Study summary

In this population study aim is to evaluate risk factors for heart failure and combine these into a new heart failure risk score.

Secondly, the heart failure risk score will be internally and externally validated, and compared with established heart failure risk scores. Additionally, the prevalence of heart failure as well as the distribution of the heart failure risk score in the general population will be evaluated.

Read the detailed description

Explore which clinical risk factors or patient characteristics in a general population that are associated with increased risk for heart failure events and combine these into a new population-based heart failure risk score ("The HUNT for heart failure risk score") for predicting heart failure risk

Validate the newly developed heart failure risk score internally in the HUNT2 database

Compare the predictive ability of the new heart failure risk score with established heart failure risk scores (the ABC Health HF risk score, the Framingham HF risk score) and an established Norwegian cardiovascular risk score (NORRISK 2)

Estimate the prevalence of likely ("undiagnosed") heart failure , i.e., patients at high risk of HF, in a general population by using both the established heart failure risk scores and the newly developed heart failure risk score, and compare the heart failure event rate between those at high risk of heart failure and those with established heart failure.

03

Conditions studied

  • Heart Failure

Keywords

  • risk factor
  • population
  • diagnosis
  • prognosis
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

General population

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participation in the third or second wave of the HUNT study

Exclusion criteria

Exclusion Criteria:

  • Not willing to participate
  • Missing vital data
05

Study design

Observational model
Ecologic or community
Time perspective
Prospective
Enrollment
36,511 participants (actual)
Target follow-up
20 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Participants in the third wave of the HUNT study

    General population participating in the third wave of the HUNT study

    Other: Heart failure risk estimation

  • Participants in the second wave of the HUNT study

    General population participating in the second wave of the HUNT study

    Other: Heart failure risk estimation

Interventions

  • OtherHeart failure risk estimation

    Evaluation by heart failure risk score

06

What researchers measure

Primary outcomes

  1. Time to incident heart failure event

    Time to first heart failure hospitalization or heart failure related visit at the out-patient clinic (events defined according to the ESC 2016 heart failure guidelines)

    Time frame: 10 years

Secondary outcomes

  1. Time to death from any cause

    Time to death from any cause

    Time frame: 10 years

  2. Time to first heart failure event or death from any cause

    Time to first heart failure event (hospitalization or HF related visit at the out-patient clinic) or death from any cause

    Time frame: 10 years

  3. Validity of heart failure risk score

    Evaluation of the validity of heart failure risk score

    Time frame: 10 years

Other outcomes

  1. Prevalence of heart failure

    Prevalence of heart failure in a general population

    Time frame: 0 days

  2. Distribution of heart failure risk score categories

    Distribution of the heart failure risk score categories in a general population

    Time frame: 0 days

07

Study locations

1 site
  • Levanger hospital
    Levanger, Norge 7600, Norway
08

References and documents

Individual participant data

Plan to share: Undecided — Will follow the institutional regulations

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Jun 2023, 68 months.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's 68 months is above that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2020
First posted
Dec 2, 2020
StartActual
Oct 1, 2017
Primary completionActual
Jun 30, 2023
CompletionActual
Jun 30, 2023
Last update
Jun 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04648852
Lead sponsor
Helse Nord-Trøndelag HF
Collaborators
Boehringer Ingelheim, Norwegian University of Science and Technology, Vestre Viken Hospital Trust
Responsible party
Sponsor
First posted
Dec 2, 2020
Start date
Oct 1, 2017
Primary completion
Jun 30, 2023
Completion
Jun 30, 2023
Last update
Jun 15, 2025

Study contacts

Håvard Dalen, MSc, PhD
study chair · Helse Nord-Trøndelag HF

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion